Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
13
LYRA Quote, Financials, Valuation and Earnings
Last price:
$0.49
Seasonality move
:
-26.45%
Day range:
$0.49 - $0.60
52-week range:
$0.31 - $37.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21.76x
P/B ratio:
3.12x
Volume:
9K
Avg. volume:
98.9K
1-year change:
-91.59%
Market cap:
$649.8K
Revenue:
$398K
EPS (TTM):
-$17.41
Analysts' Opinion
-
Consensus RatingLyra Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.00, Lyra Therapeutics, Inc. has an estimated upside of 3163.31% from its current price of $0.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $0.49.
Fair Value
-
According to the consensus of 1 analyst, Lyra Therapeutics, Inc. has 3163.31% upside to fair value with a price target of $16.00 per share.
LYRA vs. S&P 500
-
Over the past 5 trading days, Lyra Therapeutics, Inc. has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Lyra Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lyra Therapeutics, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Lyra Therapeutics, Inc. reported revenues of $25K.
Earnings Growth
-
Lyra Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Lyra Therapeutics, Inc. reported earnings per share of -$3.39.
Enterprise value:
15M
EV / Invested capital:
--
Price / LTM sales:
21.76x
EV / EBIT:
--
EV / Revenue:
37.73x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.52x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$21K
Return On Assets:
-55.34%
Net Income Margin (TTM):
-5491.17%
Return On Equity:
-493.53%
Return On Invested Capital:
-82.25%
Operating Margin:
-25032%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $1.6M | $1.5M | $398K | $209K | $7K | |
| Gross Profit | $187K | $1.1M | -$130K | $58K | -$93K | |
| Operating Income | -$65.5M | -$60.7M | -$29.6M | -$9.8M | -$6.9M | |
| EBITDA | -$65.3M | -$60.3M | -$29M | -$9.6M | -$6.8M | |
| Diluted EPS | -$1.34 | -$9.65 | -$12.95 | -$8.38 | -$3.92 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $47.9M | $100.8M | $104.8M | $43M | $16.3M | |
| Total Assets | $54.9M | $110M | $142.6M | $66.3M | $36.1M | |
| Current Liabilities | $18.2M | $14.5M | $19.6M | $12.6M | $9.5M | |
| Total Liabilities | $20.6M | $29.2M | $53.2M | $54.8M | $46.8M | |
| Total Equity | $34.3M | $80.8M | $89.4M | $11.6M | -$10.7M | |
| Total Debt | $379K | $667K | $21.4M | $30.3M | $25.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$63.3M | -$70M | -$28.9M | -$11.4M | -$6.1M | |
| Cash From Investing | -$12.6M | $80.3M | -$98K | $28.1M | -$96K | |
| Cash From Financing | $65.7M | $8.5M | $4.3M | -$1K | -- | |
| Free Cash Flow | -$64.4M | -$72.3M | -$29M | -$11.3M | -$6.2M | |
LYRA
Sector
Market Cap
$649.8K
$23.9M
Price % of 52-Week High
1.31%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
-45.37%
-1.9%
1-Year Price Total Return
-91.59%
-18.29%
Beta (5-Year)
0.297
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.49
200-day SMA
Sell
Level
$4.92
Bollinger Bands (100)
Sell
Level
1.08 - 3.64
Chaikin Money Flow
Sell
Level
-118.5K
20-day SMA
Sell
Level
$0.73
Relative Strength Index (RSI14)
Sell
Level
27.28
ADX Line
Buy
Level
24.46
Williams %R
Buy
Level
-82.2696
50-day SMA
Sell
Level
$1.24
MACD (12, 26)
Buy
Level
0.13
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-16.6K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-19.2293)
Sell
CA Score
(Annual)
Level (-5.3199)
Buy
Beneish M-Score
(Annual)
Level (-7.3943)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (10.1987)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.
Stock Forecast FAQ
In the current month, LYRA has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The LYRA average analyst price target in the past 3 months is $16.00.
-
Where Will Lyra Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lyra Therapeutics, Inc. share price will rise to $16.00 per share over the next 12 months.
-
What Do Analysts Say About Lyra Therapeutics, Inc.?
Analysts are divided on their view about Lyra Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lyra Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Lyra Therapeutics, Inc.'s Price Target?
The price target for Lyra Therapeutics, Inc. over the next 1-year time period is forecast to be $16.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is LYRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lyra Therapeutics, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of LYRA?
You can purchase shares of Lyra Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lyra Therapeutics, Inc. shares.
-
What Is The Lyra Therapeutics, Inc. Share Price Today?
Lyra Therapeutics, Inc. was last trading at $0.49 per share. This represents the most recent stock quote for Lyra Therapeutics, Inc.. Yesterday, Lyra Therapeutics, Inc. closed at $0.49 per share.
-
How To Buy Lyra Therapeutics, Inc. Stock Online?
In order to purchase Lyra Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LYRA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LYRA
Sector
P/E ratio
--
21.37x
PEG ratio
0.00x
-0.01x
P/B ratio
3.12x
1.72x
Price / LTM sales
21.76x
1.44x
Growth Metrics
LYRA
Sector
Revenue growth
-87.18%
3.44%
Earnings growth
-1766.04%
14.97%
Revenue (5-year growth)
4.6%
6.27%
Earnings forecast
-$4.06
-$0.22
Profitability
LYRA
Sector
Profitability FY 2025
-$61K
$2.4M
Return on invested capital
-82.25%
-33.43%
Return on assets
-55.34%
-29.45%
Return on equity
-493.53%
-40.29%
Earnings Date
Last Earnings Date
Apr
4
Next Earnings Date
Apr
4
Estimated Next Earnings Date
Jul
4
Balance Sheet
LYRA
Sector
Total cash
$22.1M
$25.6M
Short term investments
--
$22.7M
Total assets
$36.1M
$70.4M
Long term debt
$26.7M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
